Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found hair regrowth in the majority of AA-affected mice and rats treated with diphencyprone, suggesting its potential utility for understanding human alopecia areata and the drug's therapeutic action.

This study found that ATP may help reduce ribociclib-induced skin damage in rats by mitigating biochemical changes associated with oxidative stress.

This review reports that ritlecitinib, baricitinib, and deuruxolitinib, all JAK inhibitors, are effective treatments for moderate-to-severe alopecia areata, with differences in selectivity and onset of action, and suggests that emerging biologic therapies may enhance treatment by offering more targeted immune modulation.

This study found that more than half of patients with severe alopecia areata who reduced their baricitinib dose from 4mg to 2mg maintained a clinical response for up to 2 years.

In this study, researchers addressed the limitations of adenosine's practical application in treating inflammation, oxidative stress, and tissue repair due to its poor water solubility and low transdermal permeability. Results are not reported in the abstract.

This study formulated and characterized a dutasteride-loaded nanocrystalline suspension for long-acting parenteral delivery, finding that it provided sustained drug release in rats with a significant reduction in local inflammation over 28 days following intramuscular injection.

In this retrospective analysis, baricitinib 4 mg was found to improve hair regrowth and was deemed effective and safe for treating severe alopecia areata in a real-world setting.

This study of alopecia areata patients found that a 10 mg twice-daily dose of oral tofacitinib led to significant hair regrowth, suggesting it may be beneficial for treatment.

This study identified a novel Acinetobacter species, strain A1-4-2, with exceptional biodegradation abilities and low antibiotic resistance, found in diverse environments and potentially useful for ecological restoration by degrading organic pollutants.

In this study, researchers found that the AIRE G961C variant is a significant risk factor for severe alopecia areata and early-onset cases, particularly in patients with alopecia universalis.

This study found that transfecting alpaca melanocytes with miR-5110 altered gene expression related to pigmentation, specifically identifying pathways like MAPK and Wnt as involved in melanogenesis regulation, providing insights into miR-5110's role in pigmentation processes.

Upadacitinib effectively treats pyoderma gangrenosum.

Baricitinib effectively regrew hair in a woman with alopecia universalis after other treatments failed.

In a DNFB-induced mouse model of atopic dermatitis, this study found that both topical and oral formulations of the probiotic Bifidobacterium animalis J12 improved AD symptoms through distinct mechanisms, with topical applications reducing local inflammation and oral administration enhancing gut microbiota and reducing systemic inflammation.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

In this study, researchers developed a dissolvable microneedle patch containing baricitinib for alopecia areata treatment, reporting significantly higher hair growth in mouse models compared to controls, suggesting its potential as an effective, pain-free topical therapy.

This study introduced Cadd4, a peptide-based degrader developed using computer-aided drug design, which effectively reduced PCSK9 levels and increased LDL receptor expression, resulting in decreased plasma cholesterol and LDL-C levels in hypercholesterolemic mice, without liver toxicity.

This review discusses the condition alopecia areata and summarizes its available treatments, mentioning three recently approved Janus kinase inhibitors, but reports no new clinical results.

This study found that the optimized AR antagonist compound 39 showed potent hair growth activity with improved safety in mice, suggesting potential for better topical treatments for androgenetic alopecia.

This source reports that a network meta-analysis found oral baricitinib and ruxolitinib to be effective and safe for treating alopecia areata, significantly improving response rates over placebos and showing fewer adverse effects than steroid treatments, though precise dosing needs further study.

This study found that treating paracoccidioidomycosis-infected mice with a nanoparticle formulation of itraconazole led to higher drug accumulation in lung, liver, and spleen tissues, improved treatment efficacy, and reduced side effects compared to traditional oral solutions.

This study observed that DDAIP-HCl enhanced the permeation of minoxidil through human cadaver skin, suggesting potential for improved treatment efficacy in male pattern hair loss.

This study developed a consensus document to guide danazol discontinuation in hereditary angioedema patients, enhancing the standardization and safety of treatment protocols.

This study investigated the use of dissolving microneedle patches to improve the skin-lightening effects of alpha-arbutin and resveratrol, finding that the patches enhanced intradermal delivery and slightly decreased the melanin index without affecting skin hydration or causing irritation over 24 hours.

This study found that MPEG-dihexPLA micelles significantly improved the skin deposition of tacrolimus compared to a marketed ointment, suggesting better targeted delivery with reduced systemic absorption.

This review highlights the demonstrated efficacy and growing use of upadacitinib for cutaneous disorders, emphasizing its cost-effectiveness and recent availability in India compared to other biologics and small-molecule therapies, rather than providing new primary data.

This report observed that a patient with alopecia areata, resistant to ritlecitinib, experienced significant recovery after 24 weeks of treatment with upadacitinib, highlighting its potential in treating ritlecitinib-resistant cases and suggesting personalized treatment strategies in managing alopecia areata.

This study found that dutasteride reduced β-amyloid plaque load in a cerebral amyloidosis model, seemingly linked to mitochondrial apoptosis and autophagy processes.